Naijing Hu

Dr. Naijing Hu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
NHNaijing Hu
Naijing Hu
CQChunxia Qiao
Chunxia Qiao
JWJing Wang
Jing Wang
ZWZhihong Wang
Zhihong Wang
XLXinying Li
Xinying Li
LLlonglong luo
longlong luo

1 November 2021 in Engineering
Verified
Journal Article
Open access
HLHao Liu
Hao Liu
CQChunxia Qiao
Chunxia Qiao
NHNaijing Hu
Naijing Hu
ZWZhihong Wang
Zhihong Wang
JWJing Wang
Jing Wang
LLlonglong luo
longlong luo

14 February 2025 in Heliyon
Verified
Journal Article
Open access
NHNaijing Hu
Naijing Hu
FPFenghao Peng
Fenghao Peng
ZJZhiyang Jiang
Zhiyang Jiang
ZWZhihong Wang
Zhihong Wang
SPShangde Peng
Shangde Peng
JFJiannan Feng
Jiannan Feng
Botulinum neurotoxin (BoNT) is a highly lethal toxin produced by the anaerobic bacterium Clostridium botulinum, which leads to nerve paralysis following poisoning. At present, there is no specific drug officially approved. Antibodies, particularly single-domain antibodies, represent safe and effective candidates for specific drugs against BoNT. In this study, the receptor-binding domain of botulinum toxin (BoNT/AHCC) was utilized to immunize Bactrian camels, resulting in the generation of a nanobody phage library. From this library, a high-affinity binding antibody, designated A1, and a neutralizing antibody, named HM, were successfully obtained through SPR-based screening. The affinity constant of HM for botulinum toxin is 1.08E-11 M. Results from computer simulations indicate that HM binds at the same site as SV2C. Furthermore, experimental findings demonstrate that HM exhibits significant blocking activity at both the in vitro binding level and the cellular level. In mouse toxicity experiments, HM has been shown to offer protection against a 20 LD50 dose of BoNT/A. Consequently, HM mitigates botulinum toxin poisoning in mice by obstructing the binding of AHCC to SV2C.

29 July 2025 in Toxins
Verified
Journal Article
Open access
PDF file
SPShangde Peng
Shangde Peng
NHNaijing Hu
Naijing Hu
FPFenghao Peng
Fenghao Peng
HMHuirong Mu
Huirong Mu
ZYZihan Yi
Zihan Yi
CQChunxia Qiao
Chunxia Qiao
The C-terminus of the BoNT/A heavy chain (BoNT/AHC) mediates binding to its receptor, SV2, a critical step for toxicity. Antibody inhibition of this interaction enhances neuronal survival. We previously identified a functional anti-BoNT/AHC nanobody, HM. To extend its in vivo half-life, we designed and prepared two Fc-optimized nanoparticles, HM-Fc5 and HM-Fc6. Structural modeling (homology/docking) of the HM Fv-AHC complex predicted that HM engages key AHC residues (Tyr1155, Phe1160, Ile1161, Val1184, Asn1188, Lys1189, Glu1190), which overlap with the SV2 binding site. This suggests HM’s protective mechanism involves blocking toxin-receptor binding and cellular entry. HM-Fc5 and HM-Fc6 retained the stability and function of the parental HM antibody while exhibiting prolonged in vivo half-life. These optimized nanobodies offer economical candidates potentially enabling longer dosing intervals, beneficial for prophylaxis or chronic disease treatment. Significance Statement: The purpose of the study is to design and prepare two Fc optimized nanoparticles, HM-Fc5 and HM-Fc6, and predict the key residues involved in the interaction between HMs and AHC. The experimental results showed that HM-Fc5 and HM-Fc6 have the same stability as the parent HM antibody but have a longer half-life in vivo. The key residues Tyr1155, Phe1160, Ile1161, Val1184, Asn1188, Lys1189, and Glu1190 overlap with the SV2 binding site. Our experimental results indicate that these nanobody candidates are not only more economical and convenient, but may also have longer dosing intervals, providing strong evidence and reference for prolonging the in vivo half-life of nanomaterials.